Currently, Celldex Therapeutics Inc [CLDX] is trading at $19.39, up 2.38%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CLDX shares have gain 8.99% over the last week, with a monthly amount drifted -1.27%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Celldex Therapeutics Inc [NASDAQ: CLDX] stock has seen the most recent analyst activity on March 20, 2025, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $46. Previously, UBS started tracking the stock with Buy rating on February 13, 2025, and set its price target to $44. On October 07, 2024, Citigroup initiated with a Buy rating and assigned a price target of $70 on the stock. Goldman started tracking the stock assigning a Neutral rating and suggested a price target of $45 on September 30, 2024. Wolfe Research downgraded its rating to a Peer Perform. Stifel started tracking with a Buy rating for this stock on June 18, 2024, and assigned it a price target of $58. In a note dated June 11, 2024, Wolfe Research initiated an Outperform rating and provided a target price of $51 on this stock.
This stock has fluctuated between a low of $14.40 and a high of $47.00 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $63 within the next 12 months. Celldex Therapeutics Inc [NASDAQ: CLDX] shares were valued at $19.39 at the most recent close of the market. An investor can expect a potential return of 224.91% based on the average CLDX price forecast.
Analyzing the CLDX fundamentals
Trailing Twelve Months sales for Celldex Therapeutics Inc [NASDAQ:CLDX] were 7.02M which represents -71.56% decline. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -27.79%, Pretax Profit Margin comes in at -22.49%, and Net Profit Margin reading is -22.49%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.2 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.04 points at the first support level, and at 18.68 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.58, and for the 2nd resistance point, it is at 19.76.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Celldex Therapeutics Inc [NASDAQ:CLDX] is 18.91. Also, the Quick Ratio is 18.91, while the Cash Ratio stands at 0.72. Considering the valuation of this stock, the price to sales ratio is 183.36, the price to book ratio is 1.72.
Transactions by insiders
Recent insider trading involved Marucci Anthony S, PRESIDENT & CEO, that happened on Nov 11 ’24 when 11500.0 shares were purchased. SVP AND CFO, Martin Samuel Bates completed a deal on Jun 14 ’24 to sell 17172.0 shares. Meanwhile, SR. VP & CPDO Crowley Elizabeth sold 30000.0 shares on Jun 14 ’24.
